Clinical Trial Update: Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating tenapanor as core therapy for hyperphosphatemia in chronic kidney disease patients on dialysis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperphosphatemia

Drugs mentioned

• Tenapanor (tenapanor)

Snippet

Sponsor: Ardelyx | Conditions: Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia | Phase 4 | Status: COMPLETED | Results posted: 2023-03-29